# XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

> **NCT05875402** · NA · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 9 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Chimeric antigen receptor T cell preparation targeting GCC

## Key facts

- **NCT ID:** NCT05875402
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2023-12-28
- **Final completion:** 2025-05-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875402, "XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05875402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*